The history of biomarker development for epidermal growth factor receptor (EGFR) monoclonal antibodies for patients with colorectal cancer has been a convoluted path. Each development has provided ...
RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Biweekly mXELIRI versus FOLFIRI in combination with ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval. According to the National Cancer ...
July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
Investigators in Sweden recently examined how KRAS mutations impact overall survival (OS) in a population of patients with stage IV NSCLC. Among patients who received ICB, those with KRAS mutations ...
Bottom line: Colorectal cancer and pancreatic ductal adenocarcinoma that harbored the KRAS G12C mutation often carried other genetic alterations that can be associated with resistance to KRAS G12C ...
Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments. One of the key problems with identifying and acting ...
Mutations of KRAS have long been targets of interest for the development of new cancer therapies, but structural changes caused by these mutations have made it particularly difficult to target and ...
A recommendation to test for the mutation aligns with calls to identify biomarkers in cholangiocarcinoma to guide treatment. Testing for this mutation could guide treatment, wrote investigators from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback